Table 2.
Clinical advancement of HSP90 inhibitors for cancer therapy in a combinatorial approach.
| HSP90 inhibitor | Year | Combination | Clinical status (Phases) | NCT no. | Status | Outcome/Indication | References |
|---|---|---|---|---|---|---|---|
| 17AAG | 2005 | I | NCT00003969 | C | Advanced cancer | 434 | |
| I | NCT00003969 | C | Advanced cancer | 435 | |||
| I | NCT00003969 | C | Advanced malignancy | 436 | |||
| I | NCT00003969 | C | Solid tumors | 437 | |||
| 2006 | I | NCT00003969 | C | Advanced cancer | 438 | ||
| II | N/A | – | Renal cell carcinoma | 439 | |||
| 2007 | I | NCT00003969 | C | Advanced cancer | 440 | ||
| Trastuzumab | I | N/A | – | HER2-positive BC | 441 | ||
| I | NCT00003969 | C | Advanced cancers | 442 | |||
| I | NCT00079404 | C | Pediatric solid tumors | 443 | |||
| I | NCT00079404 | C | Pediatric solid tumors | 444 | |||
| 2008 | Irinotecan | I | NCT00119236 | C | Solid tumors | 445 | |
| II | NCT00118092 | C | Prostate cancer | 446 | |||
| II | NCT00104897 | C | Metastatic melanoma | 447 | |||
| Paclitaxel | I | NCT00087217 | C | Solid tumors | 448 | ||
| 2010 | Bortezomib | II | N/A | – | Multiple melanoma | 449 | |
| Sorafenib | I | NCT00121264 | C | Solid tumors | 450 | ||
| I | NCT0051437/NCT00546780 | C | Multiple myeloma | 451 | |||
| Gemcitabine or cisplatin | I | NCT00047047 | C | Solid tumors | 452 | ||
| 2011 | Trastuzumab | II | NCT00773344 | C | HER2-positive BC | 453 | |
| Cytarabine | I | NCT00098423 | C | Acute leukemia | 454 | ||
| Docetaxel | I | NCT00058253 | C | Solid tumors | 455 | ||
| Gemcitabine | II | NCT00093496 | C | EPC and PPC | 456 | ||
| Bortezomib | I/II | NCT00514371 | C | Multiple myeloma | 457 | ||
| 2012 | II | N/A | – | Breast cancer | 458 | ||
| II | NCT00104897 | C | Metastatic melanoma | 459 | |||
| 2013 | Bortezomib | I | NCT00096005 | T | Solid malignancies | 460 | |
| Bortezomib | I | N/A | – | AML | 461 | ||
| 2015 | Gemcitabine | II | NCT00577889 | C | Pancreatic cancer | 462 | |
| 17-DMAG | 2010 | I | NCT00089362 | C | Solid tumors | 442 | |
| I | NCT00088868 | C | Advanced malignancy | 463 | |||
| I | NCT0008927/NCT00088868 | C | AML | 464 | |||
| 2011 | I | NCT00248521 | U | Solid tumors | 465 | ||
| 2012 | Trastuzumab | I | N/A | – | Solid tumors | 466 | |
| 2016 | I | NCT01126502 | W | CLL/ALL | 467 | ||
| AT13387 | 2015 | I | NCT01246102 | C | Solid tumors | 468 | |
| I | NCT00878423 | C | Solid tumors | 469 | |||
| 2016 | Talazoparib | I | NCT02627430 | W | Ovarian cancer, FTC, PPC, TNBC | 470 | |
| 2021 | AT7519 | I | NCT02503709 | A | Solid tumors | 471 | |
| Olaparib | I | NCT02898207 | A | Ovarian cancer, FTC, PPC and TNBC | 472 | ||
| Cisplatin and radiation | I | NCT02381535 | A | SCC of the head and neck | 473 | ||
| Paclitaxel | I | NCT02474173 | A | TNBC | 474 | ||
| AUY922 | 2013 | I | N/A | Solid tumors | 475 | ||
| 2014 | 89Zr-trastuzumab/bevacizumab | I | NCT01081613/NCT01081600 | C | Breast cancer | 476 | |
| 2015 | Bortezomib | I/Ib | NCT00708292 | C | Multiple myeloma | 477 | |
| Capecitabine | I | NCT01226732 | C | Solid tumors | 478 | ||
| 2016 | II | NCT01404650 | C | GIST | 479 | ||
| II | NCT01124864 | C | NSCLC | 480 | |||
| II | NCT01668173 | T | MPNs | 481 | |||
| 2017 | II | NCT01485536 | T | Lymphoma | 482 | ||
| 2019 | II | NCT01646125 | T | NSCLC | 483 | ||
| Erlotinib | I/II | NCT01259089 | C | Lung ADC, NSCLC | 484 | ||
| 2020 | Pemetrexed | I | NCT01784640 | C | NSCLC, lung cancer | 485 | |
| BIIB021 | 2013 | II | NCT00618319 | C | GIST | 486 | |
| 2014 | I | NCT00618735 | C | Solid tumors | 487 | ||
| BIIB028 | 2013 | I | NCT00725933 | C | Solid tumors | 488 | |
| Debio0932 | 2015 | I | NCT01168752 | C | Advanced cancer | 489 | |
| HSP990 | 2015 | I | NCT00879905 | C | Solid tumors | 490 | |
| IPI-504 | 2011 | I | NCT00113204 | C | Multiple myeloma | 491 | |
| 2013 | I | NCT00276302 | C | GIST and sarcomas | 492 | ||
| 2017 | II | NCT01228435 | T | Lung cancer | 493 | ||
| KW-2478 | 2014 | Bortezomib | I/II | NCT01063907 | C | Multiple melanoma | 494 |
| 2016 | I | NCT00457782 | C | B-cell malignancy | 495 | ||
| SNX-5422 | 2011 | I | NCT00647764 | C | ST's and lymphomas | 496 | |
| 2013 | I | NCT00595686 | C | Malignant hematology | 497 | ||
| 2017 | I/II | NCT01848756 | T | HER2 positive cancers | 498 | ||
| 2018 | II | NCT02612285 | T | TP53 null cancers | 499 | ||
| 2019 | Lbrutinib | I | NCT02973399 | T | CLL | 500 | |
| STA-9090 | 2013 | I | NCT00687934 | C | Solid tumors | 501 | |
| II | NCT01562015 | C | Advanced NSCLC | 502 | |||
| 2014 | II | NCT01111838 | C | Metastatic CRC | 503 | ||
| II | NCT01227018 | T | Pancreas cancer | 507 | |||
| 2015 | Docetaxel | II | NCT01348126 | T | Advanced NSCLC | 504 | |
| 2016 | II | NCT01270880 | C | Prostate cancer | 505 | ||
| I | NCT02334319 | T | Head and neck cancer | 508 | |||
| Paclitaxel | II | NCT02637375 | W | Breast cancer | 509 | ||
| 2017 | II | NCT01551693 | T | Melanoma | 510 | ||
| 2018 | II | NCT01200238 | C | Ocular melanoma | 511 | ||
| Paclitaxel/Trastuzumab | I | NCT02060253 | C | HER2-positive BC | 512 | ||
| Ziv-aflibercept | I | NCT02192541 | T | UC, GIST & NSCLC | 513 | ||
| 2019 | II | NCT01173523 | C | SCLC | 514 | ||
| I/II | NCT02012192 | T | EPC, FTC and PPC | 515 | |||
| Sirolimus | I/II | NCT02008877 | C | MPNST, sarcoma | 516 | ||
| 2020 | Docetaxel | III | NCT01798485 | T | NSCLC | 506 | |
| PU-H71 | 2017 | I | NCT01581541 | T | ST's, lymphoma | 517 | |
| 2020 | Ruxolitinib | I | NCT03935555 | R | PMF, Post-PV MF, Post-ET MF | 518 | |
| TAS-116 | 2019 | I | NCT02965885 | C | Solid tumors | 519 | |
| NVP-BEP800 | 2020 | – | NCT04437420 | R | T-ALL, B-ALL | 520 | |
| CUDC 305 | 2019 | I | NCT03675542 | R | Psoriasis vulgaris | 521 | |
| TQB3474 | 2019 | I | NCT04144855 | R | Solid tumors | 522 | |
| PEN-866 | 2021 | I/II | NCT03221400 | R | Solid tumors | 523 | |
| RTA-901 | 2017 | I | NCT02666963 | C | Healthy adults | 524 | |
| XL888 | 2020 | Pembrolizumab | I | NCT03095781 | R | GIST | 525 |
| 2021 | Vemurafenib /Cobimetinib |
I | NCT02721459 | A | Melanoma | 526 |
Abbreviations C: Completed; T: Terminated; R: Recruiting; U: Unknown; A: Active; W: Withdrawn; N/A: Not available; CLL: Chronic lymphocytic leukemia; SLL: Small lymphocytic lymphoma; NSCLC: Non-small cell lung cancer; GIST: Gastrointestinal stromal tumors; T-ALL: T-cell acute lymphocytic leukemia; B-ALL: B-cell acute lymphocytic leukemia; PMF: Primary myelofibrosis; Post-PV MF: Post-polycythemia vera myelofibrosis; Post-ET MF: Post-essential thrombocythemia myelofibrosis; MPNST: Malignant peripheral nerve sheath tumor; SCLC: Small cell lung cancer; TP53: Tumor protein P53; TNBC: Triple negative breast cancer; SCC: Squamous cell carcinoma; CRC: Colorectal cancer; MPNs: Myeloproliferative neoplasms; EPC: Epithelial ovarian cancer; FTC: Fallopian tube cancer; PPC: Primary peritoneal cancer; BC: Breast cancer; AML: Acute myloid leukemia; ST's: Solid tumors; UC: Urothelial carcinoma; Lung ADC: Lung adenocarcinoma.